Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 1998

View Archived Issues

Company Profile: GenVec

Prodrug of platelet gpIIb/IIIa receptor antagonist with excellent intranasal antithrombotic efficacy

Cerus presents preclinical data on RBC pathogen inactivation system and begins clinical trials

European merger mania continues with the proposed formation of AstraZeneca

CoCensys patents key cell death gene, will license the technology out

U.S. patent covers Coulter's antibody therapy for B-cell lymphoma

Magainin scientists identify new therapeutic target for asthma: interleukin-9

Banyu conducts PK and metabolic studies of topoisomerase I inhibitor

Merck & Co. revises safety information on Singulair for U.S. healthcare professionals

Excellent results obtained in AML patients receiving Maxamine plus IL-2

CIMA reports significant transmucosal absorption-enhancing effects for OraVescent

First report of efficacy of oral, sustained-release fampridine in SCI

Pharmacyclics' photoangioplasty a hot topic at RSNA

LY-303366: therapeutic and prophylactic efficacy in pulmonary aspergillosis in neutropenic animals

FDA advisory committee will meet in January to review KeraVision Ring PMA

Hemosol completes patient recruitment in phase II trial with Hemolink

New approval obtained for Nycomed's Xefo

CMA-676 shows efficacy and excellent tolerability in patients with AML

Aronex files first NDA for orphan drug for APL

J&J to terminate collaboration with Ergo Science for Ergoset development

Lilly obtains exclusive worldwide rights to (R)-fluoxetine

Techniclone initiates phase II trial for treatment of malignant glioma

Competitive LPS antagonist E-5531 suppresses LPS-mediated effects in vitro and in vivo

Candidate antidepressants available for licensing from Berkeley Lab

Avant receives further payment from Novartis for TP-10 development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...